APPRAISE-2 Study with Investigational Compound Apixaban Discontinued
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy.
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment
- Details
- Category: Novartis
Novartis presented a strategic overview of the company's diversified healthcare portfolio which creates the potential for future sustainable growth. The company's focused healthcare portfolio across key growth segments in healthcare provides Novartis a leading position in the respective market segments.
Genzyme Announces Agreement to Sell Diagnostics Business
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) announced that it has entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme's Diagnostic products business for $265 million in cash.
Pfizer Launches Global Centers for Therapeutic Innovation
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers.
Roche announces implementation plans for its Operational Excellence Program
- Details
- Category: Roche
Roche disclosed the measures it plans to take as part of its Group-wide Operational Excellence Program, announced in September. The initiative is a response to mounting cost pressures in healthcare - particularly in the US and Europe - and to increasing hurdles for the approval and pricing of new medicines.
Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim employees across the globe were called to action in support of this year's World Diabetes Day. Equipped with pedometers for a week, each step taken by employees was counted and converted into a contribution of 15.000 Euros in support of the International Diabetes Federation's (IDF) "Life for a Child" Programme.
Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization for patients with chronic heart failure with mild symptoms treated with Inspra® (eplerenone) versus those given placebo in addition to standard HF therapy.
More Pharma News ...
- Rivaroxaban Significantly Reduces Risk of Stroke with Comparable Safety versus Warfarin
- Diabetes awareness survey reveals alarming figures across the Middle East and Northern Africa regions
- Collaboration of Boehringer Ingelheim and VTU Technology
- Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis
- Nycomed is keeping the pace in third quarter 2010
- Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent
- Roche reports promising Phase II results with new targeted approach in advanced melanoma